Exelon in Vascular Dementia "VantagE"

Completed

Phase N/A Results

Summary of Purpose

To compare the safety and efficacy of rivastigmine (Exelon) with those of extended-release aspirin (Cardioaspirin) in vascular dementia patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 September 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Novartis

Trial Design

Randomized, controlled trial.

Contacts

Not available